Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.

The decline outpaced the S&P 500 as Merck’s October earnings report approaches, with consensus forecasts pointing to lower quarterly earnings.

Johnson & Johnson shares climbed despite slower revenue growth, as investors weigh new-drug momentum against Stelara losses and softer MedTech sales.

The Florida Republican disclosed a cluster of August trades spanning SpaceX, Berkshire Hathaway, biotech and technology stocks.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.